Levin Capital Strategies’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Levin Capital Strategies’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,377	Closed	-$748K	–	297
2023 Q4	$748K	Buy	+8,377	New	+$622K	0.08%	109
2015 Q4	–	Sell	-9,000	Closed	-$560K	–	380
2015 Q3	$560K	Sell	9,000 -3,000	-25%	-$236K	0.01%	239
2015 Q2	$1.01M	Buy	+12,000	New	+$933K	0.01%	206
2014 Q4	–	Sell	-55,191	Closed	-$2.87M	–	423
2014 Q3	$2.87M	Buy	+55,191	New	+$2.81M	0.04%	157

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Levin Capital Strategies's XBI Position: Q1 2024 in Review

Levin Capital Strategies sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 8,377 shares — an estimated $748K sold.

Levin Capital Strategies first reported a position in XBI in Q3 2014 and held it in 4 quarters. The position peaked at $2.87M in Q3 2014. 781 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Levin Capital Strategies reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
Levin Capital Strategies sold 8,377 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $748K.
Levin Capital Strategies first reported a position in State Street SPDR S&P Biotech ETF in Q3 2014 and held it in 4 quarters.
Levin Capital Strategies's State Street SPDR S&P Biotech ETF position peaked at $2.87M in Q3 2014.
781 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Levin Capital Strategies's 13F filing for Q1 2024, filed 16 May 2024.